Medicenna Therapeutics Corp. Common Shares
MDNA
MDNA was delisted on the 1st of November, 2023.
25 hedge funds and large institutions have $2.41M invested in Medicenna Therapeutics Corp. Common Shares in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 4 closing their positions.
7% less funds holding
Funds holding: 27 → 25 (-2)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
42% less capital invested
Capital invested by funds: $4.15M → $2.41M (-$1.74M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$128K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$21.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$10.7K |
| 4 |
Millennium Management
New York
|
+$9.71K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$8.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$318K |
| 2 |
AC
Annandale Capital
Dallas,
Texas
|
-$19K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16.8K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$13.3K |
| 5 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
-$6.22K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DCM
26
DAFNA Capital Management
Los Angeles,
California
| – | -$318K | -660,000 | Closed |
|
|
AC
27
Annandale Capital
Dallas,
Texas
| – | -$19K | -40,000 | Closed |
|
|
NDSI
28
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
| – | -$6.22K | -12,915 | Closed |
|
29
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$272 | -600 | Closed |
|
MDNA Hedge Fund Activity: Q3 2023 in Review
25 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q3 2023, worth a combined $2.41M — down 42% from $4.15M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MDNA and 2 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Sigma Planning Corp, adding an estimated $128K. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $318K sold.
- 25 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q3 2023, down from 27 in Q2 2023.
- Funds reported $2.41M of Medicenna Therapeutics Corp. Common Shares stock for Q3 2023, down 42% quarter-over-quarter.
- 2 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q3 2023 and 4 closed out, a net change of -2 holders.
- The largest Medicenna Therapeutics Corp. Common Shares buyer in Q3 2023 was Sigma Planning Corp, an estimated $128K added.
- The largest Medicenna Therapeutics Corp. Common Shares seller in Q3 2023 was DAFNA Capital Management, an estimated $318K sold.
Based on aggregated 13F filings for Q3 2023.